Safe Antidepressant in Heart Block
Sertraline is the safest antidepressant choice for patients with heart block, as it has negligible QT-prolonging effects and does not affect cardiac conduction. 1
Primary Recommendation
Among selective serotonin reuptake inhibitors (SSRIs), sertraline and paroxetine carry negligible risk of QT prolongation, while citalopram and escitalopram pose the highest risk within this class 1. Given that heart block patients are already at risk for conduction abnormalities, avoiding any additional cardiac conduction effects is paramount.
Medications to Absolutely Avoid
Tricyclic antidepressants (TCAs) are contraindicated in patients with heart block. These agents:
- Delay AV-node conduction, directly worsening heart block 2
- Act as type IA antiarrhythmics with quinidine-like effects 3
- Cause hypotension, worsening heart failure, and arrhythmias 4
- Carry significantly increased cardiac arrest risk (OR = 1.69) 2
The evidence is particularly strong against amitriptyline and maprotiline, which have documented cases of complete AV block 2.
Alternative Safe Options
If sertraline is ineffective or not tolerated:
- Paroxetine - Also has negligible QT effects 1
- Bupropion - Safer cardiovascular profile than TCAs 5
- SNRIs (serotonin-norepinephrine reuptake inhibitors) - No association with cardiac arrest in registry studies 2
Critical Monitoring Considerations
Even with safer agents, patients with heart block require:
- Baseline ECG before initiating any antidepressant 1
- Electrolyte monitoring (potassium >4.5 mEq/L, magnesium) 1
- Avoid combining with other QT-prolonging drugs (check www.crediblemeds.org) 1
- Serial ECG monitoring if borderline QTc or multiple risk factors 1
Important Caveats
Women and elderly patients face higher risk of drug-induced arrhythmias 1. The presence of structural heart disease further increases vulnerability to conduction disturbances 1.
If the patient has underlying ischemic heart disease in addition to heart block, SSRIs (particularly sertraline) remain the preferred choice, as they have been specifically studied and found safe in post-MI populations 6, 5.
Do not use escitalopram or citalopram - despite being SSRIs, the FDA and EMA have restricted their maximum doses due to QT prolongation risk, with further dose reductions required in patients over 60 years 2.
The key principle: prioritize agents with no effect on cardiac conduction over those that prolong repolarization or affect AV nodal function, as heart block patients cannot tolerate additional conduction system compromise 1, 2.